Supreme Court Leaves FDA To Its Own Devices In Regulating Fraud Claims
This article was originally published in The Gray Sheet
Executive Summary
The Supreme Court's Feb. 21 decision in Buckman Co. v. Plaintiffs Legal Committee defends off-label use as a vital "corollary" to FDA's regulatory scheme, while also investing sole authority in the agency to determine whether premarket submissions are fraudulent.